Drug Profile
Research programme: anticancer protein therapeutics - Advanced Proteome Therapeutics
Alternative Names: Anticancer multimers - Advanced Proteome Therapeutics; Anticancer protein-drug conjugates - Advanced Proteome Therapeutics; APC 101; APC 102; APC 103Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Advanced Proteome Therapeutics
- Class Drug conjugates; Proteins; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Cell death stimulants; Cell movement activators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Sarcoma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Jul 2018 No recent reports of development identified for research development in Sarcoma in USA